Department of Medical Genetics, Policlinico Sant'Orsola-Malpighi, University of Bologna, Bologna, Italy.
Am J Med Genet A. 2013 May;161A(5):1028-35. doi: 10.1002/ajmg.a.35852. Epub 2013 Mar 29.
Recently, mutations in the SMAD3 gene were found to cause a new autosomal dominant aneurysm condition similar to Loeys-Dietz syndrome (LDS), mostly with osteoarthritis, called aneurysms-osteoarthritis syndrome (AOS). Our 3-year-old propositus underwent correction of an inguinal hernia at 3 months and substitution of the ascending aorta for pathologic dilation at 12 months of age. Family history reveals aortic dilation in his mother at 30 years, death due to aortic dissection of an 18-year-old maternal aunt, surgical replacement of the ascending aorta because of aneurysm in a maternal uncle at 19 years, postpartum death of the maternal grandmother at 24 years and surgical intervention because of thoracic aortic aneurysm in a brother of the propositus' grandmother at 54 years. The affected individuals present with several other signs of connective tissue disease, but the two adult patients evaluated revealed no radiologic evidence of osteoarthritis. Molecular testing of the TGFBR1 and TGFBR2 genes, involved in LDS, resulted negative, but analysis of SMAD3 disclosed the novel heterozygous loss-of-function mutation c.1170_1179del (p.Ser391AlafsX7) in exon 9 in all affected family members, confirming the diagnosis of AOS. SMAD3 mutations should be considered in patients of all ages with LDS-like phenotypes and negative TGFBR1/2 molecular tests, especially in the presence of aortic root or ascending aortic aneurysms, even though signs of early onset osteoarthritis are absent.
最近,SMAD3 基因突变被发现导致一种新的常染色体显性动脉瘤疾病,类似于 Loeys-Dietz 综合征(LDS),主要伴有骨关节炎,称为动脉瘤-骨关节炎综合征(AOS)。我们的 3 岁先证者在 3 个月时接受了腹股沟疝的矫正,在 12 个月时接受了升主动脉置换以治疗病理性扩张。家族史显示,其母亲在 30 岁时出现主动脉扩张,18 岁的姑妈因主动脉夹层死亡,19 岁的舅舅因升主动脉动脉瘤接受手术置换,24 岁的祖母因产后去世,54 岁时祖母的兄弟因胸主动脉瘤接受手术干预。受影响的个体还存在其他几种结缔组织疾病的迹象,但评估的两名成年患者均未发现骨关节炎的放射学证据。涉及 LDS 的 TGFBR1 和 TGFBR2 基因的分子检测结果为阴性,但 SMAD3 分析显示,所有受影响的家族成员在外显子 9 中均存在新的杂合性功能丧失突变 c.1170_1179del(p.Ser391AlafsX7),证实了 AOS 的诊断。SMAD3 突变应考虑在具有 LDS 样表型和 TGFBR1/2 分子检测阴性的所有年龄段的患者中,尤其是在存在主动脉根部或升主动脉动脉瘤的情况下,即使不存在早期骨关节炎的迹象。